November 11, 2020 – Abbott (Abbott Park, IL) announced the launch of the IonicRF Generator, a new device recently cleared by the U.S. Food and Drug Administration (FDA) to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system.
The IonicRF Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain. The new device is the first Abbott-developed radiofrequency ablation device and is currently approved in the U.S. and Europe.
“Most people who are candidates for radiofrequency ablation have tried other therapies, such as medications and injections, with limited success. As a result, they are now seeking an alternative solution that does not require surgery or the use of opioid medication,” said Keith Boettiger, vice president, Neuromodulation, Abbott. “We are proud to be able to provide the first Abbott-designed radiofrequency ablation device engineered to deliver safe and effective pain management. This is another example of our focus on widening the breadth of our neuromodulation portfolio and keeping patients central to everything we do at Abbott.”